Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
18.31
-0.01 (-0.03%)
Nov 5, 2024, 1:15 PM EST - Market open

Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.

It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.

The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings logo
Country United States
Founded 2009
Industry Biotechnology
Sector Healthcare
Employees 19
CEO Yuval Cohen

Contact Details

Address:
500 River Ridge Drive
Norwood, Massachusetts 02062
United States
Phone 617 963 0100
Website corbuspharma.com

Stock Details

Ticker Symbol CRBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001595097
CUSIP Number 21833P103
ISIN Number US21833P3010
Employer ID 46-4348039
SIC Code 2834

Key Executives

Name Position
Dr. Yuval Cohen Ph.D. Chief Executive Officer and Director
Sean F. Moran CPA, M.B.A. Chief Financial Officer
Lindsey Smith Head of Corporate Communications and Patient Advocacy
Christina Bertsch Vice President of Human Resources
Dr. Dominic Smethurst M.A., M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 8-K Current Report
Oct 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 15, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 11, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 4, 2024 144 Filing
Sep 3, 2024 8-K Current Report
Aug 20, 2024 8-K Current Report
Aug 6, 2024 8-K Current Report
Aug 6, 2024 10-Q Quarterly Report